3681 Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
SinoMab BioScience Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.60 |
52 Week High | HK$1.95 |
52 Week Low | HK$1.03 |
Beta | 0.72 |
11 Month Change | -2.44% |
3 Month Change | -12.57% |
1 Year Change | 4.58% |
33 Year Change | -52.94% |
5 Year Change | n/a |
Change since IPO | -73.33% |
Recent News & Updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Shareholder Returns
3681 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -2.4% | 6.5% | -1.7% |
1Y | 4.6% | -26.3% | -5.9% |
Return vs Industry: 3681 exceeded the Hong Kong Biotechs industry which returned -26.3% over the past year.
Return vs Market: 3681 exceeded the Hong Kong Market which returned -5.9% over the past year.
Price Volatility
3681 volatility | |
---|---|
3681 Average Weekly Movement | 5.2% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 3681 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3681's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 215 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus.
SinoMab BioScience Limited Fundamentals Summary
3681 fundamental statistics | |
---|---|
Market cap | HK$1.74b |
Earnings (TTM) | -HK$264.54m |
Revenue (TTM) | HK$4.78m |
365.5x
P/S Ratio-6.6x
P/E RatioIs 3681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3681 income statement (TTM) | |
---|---|
Revenue | CN¥4.39m |
Cost of Revenue | CN¥943.00k |
Gross Profit | CN¥3.45m |
Other Expenses | CN¥246.56m |
Earnings | -CN¥243.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 19, 2024
Earnings per share (EPS) | -0.22 |
Gross Margin | 78.53% |
Net Profit Margin | -5,535.31% |
Debt/Equity Ratio | 132.4% |
How did 3681 perform over the long term?
See historical performance and comparison